Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy.
about
Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory AgentsThe CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell functionIn vitro effects of the small-molecule protein kinase C agonists on HIV latency reactivation.Landscape review of current HIV 'kick and kill' cure research - some kicking, not enough killing.HIV-1 Latency-Reversing Agents Prostratin and Bryostatin-1 Induce Blood-Brain Barrier Disruption/Inflammation and Modulate Leukocyte Adhesion/Transmigration.Cancer therapies in HIV cure research.Toll-Like Receptor 7 Agonist GS-9620 Induces HIV Expression and HIV-Specific Immunity in Cells from HIV-Infected Individuals on Suppressive Antiretroviral TherapyThe Alphabet Soup of HIV Reservoir Markers.Proviral Latency, Persistent Human Immunodeficiency Virus Infection, and the Development of Latency Reversing Agents.HIV-hepatitis B virus co-infection: epidemiology, pathogenesis, and treatment.HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal.Combinations of isoform-targeted histone deacetylase inhibitors and bryostatin analogues display remarkable potency to activate latent HIV without global T-cell activation.Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency.In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and "kill" in strategy for virus eradication.Evaluation of Chromane-Based Bryostatin Analogues Prepared via Hydrogen-Mediated C-C Bond Formation: Potency Does Not Confer Bryostatin-like Biology.Contrasting effect of the latency-reversing agents bryostatin-1 and JQ1 on astrocyte-mediated neuroinflammation and brain neutrophil invasion.Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells.Getting the "Kill" into "Shock and Kill": Strategies to Eliminate Latent HIV.Scalable synthesis of bryostatin 1 and analogs, adjuvant leads against latent HIV.Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents.Tackling HIV Persistence: Pharmacological versus CRISPR-Based Shock Strategies.Novel Latency Reversal Agents for HIV-1 Cure.Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents.Diverse Impacts of HIV Latency-Reversing Agents on CD8+ T-Cell Function: Implications for HIV Cure.Combination of a Latency-Reversing Agent With a Smac Mimetic Minimizes Secondary HIV-1 InfectionExposure to Prostratin but Not Bryostatin-1 Improves Natural Killer Cell Functions Including Killing of CD4 T Cells Harboring Reactivated Human Immunodeficiency VirusAntibodies and Antibody Derivatives: New Partners in HIV Eradication Strategies
P2860
Q28079455-551ECF47-0E30-4800-B6B0-F6DB8CB75F70Q33725916-B252B3BA-0877-4B59-8038-A4D7879295A3Q37144949-80ED1B65-E601-487B-9DB9-0CC1502FD721Q37493633-5FC41FE4-18FB-4631-85E0-651B62AC7518Q38636019-33D1B271-AC8C-40DE-B1F0-112B5F12D63EQ38725384-C3246AD3-A0FB-433A-A454-EBA2C3F32618Q38949445-F473C41B-8BCB-4DEE-91B0-C01E92EB226FQ38971085-1FD7E3FF-A3C9-4BC2-B8AE-9D2CA464ED0EQ39237000-F054965B-F3C7-44DE-9E0B-680AF2D67DECQ39315697-E80DBDB4-A80A-4701-97CC-1645291FCA24Q39425755-A56962F6-2363-4C74-9F95-1F9B5ED5D484Q40080802-92CDB5B5-CD36-4A09-9C38-9C4C8A2ED6F3Q40091545-EA204CDC-07A6-453F-9D52-F575FE573E31Q40120304-60892B4C-5D0D-4CF4-BA9A-2B9D4CDC91E7Q41932886-34D9529E-69A0-4037-A4BF-9DA8262D9825Q42135531-E35052A0-6E57-483F-A2BA-D66CCD87782AQ47147442-00F627A4-1533-472A-AC58-94CE65974347Q47550536-3B70E84E-4206-4CEC-ADDB-F58FBF764B67Q47555333-743EBDBA-CDD7-45C9-9BDC-061B7E2E2F8BQ47614932-F124F8FB-BA6C-4F71-9E64-30FCBA6D449FQ49925023-62950213-0142-420B-AF94-BA66EDB916C3Q52431127-63CD308F-ABF2-42B6-BE77-E8DDF8FD017AQ52816327-A348B4EC-ACF6-43AE-9984-043B88E94448Q54978212-5F65AA95-2C6E-43D1-B42F-9EC1E2B75320Q55455666-74EF4AA8-CCB1-43FA-914F-E7AA54854605Q57072848-9734AEA6-3A9A-4D75-8CD5-0D9FD41C6082Q57565007-F6EC50AE-A0A5-419F-A7F7-60BBB60DAB7EQ58572618-6BEA660D-E913-43C3-A2B8-FA44F1500E39
P2860
Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Bryostatin-1 for latent virus ...... nts on antiretroviral therapy.
@en
type
label
Bryostatin-1 for latent virus ...... nts on antiretroviral therapy.
@en
prefLabel
Bryostatin-1 for latent virus ...... nts on antiretroviral therapy.
@en
P2093
P50
P921
P1433
P1476
Bryostatin-1 for latent virus ...... nts on antiretroviral therapy.
@en
P2093
Carolina Gutiérrez
Javier Ruipérez
Nadia Madrid-Elena
Santiago Moreno
Trevor Castor
P304
P356
10.1097/QAD.0000000000001064
P407
P50
P577
2016-02-17T00:00:00Z